Refine Results
- 必威体育赛事投注
- Applications and Industries
-
- Content Type
-
Content Type
- Analysis Platform
-
Product
- Language
-
Language
Applied Filters
In this application note, Antibody Analytics (Motherwell, UK) integrates IndEx-2, an advanced in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels, with the...
- Publication Part Number: 5994-7175EN
- Created: 06 June 2024
- 2 MB
This application note demonstrates the signal recording of the xCELLigence RTCA eSight, enabling visualization and quantification of cell migration and invasion and the speed of wound closure healing.
- Publication Part Number: 5994-6887EN
- Created: 08 Dec 2023
- 13 MB
This application note describes a novel real-time co-culture assay using RTCA eSight for interrogating NK92 immune cell invasion and cytotoxicity and migratory kinetic profiles based on ECM and effects of TME.
- Publication Part Number: 5994-6888EN
- Created: 29 Nov 2023
- 3 MB
必威体育登录手机This application note evaluates the Agilent xCELLigence RTCA eSight as a tool to monitor BiTE antibody-mediated cancer cell lysis.
- Publication Part Number: 5994-6004EN
- Created: 21 Apr 2023
- 2 MB
xCELLigence Immunotherapy IMT Assay (anti-CD9) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3234EN
- Created: 15 Mar 2022
- 634 KB
必威体育登录手机This study used the Agilent xCELLigence RTCA CardioECR system with human iPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiac safety/toxicity of antiviral drugs.
- Publication Part Number: 5994-4325EN
- Created: 15 Nov 2021
- 2 MB
必威体育登录手机Agilent xCELLigence Immunotherapy Kit
- Publication Part Number: 5994-1597EN
- Created: 13 Oct 2021
- 4 MB
必威体育登录手机A demonstration of the use of the Agilent xCELLigence RTCA CardioECR system to compare functional profiles of contractility and electrophysiology between an PS-iPSC-CM disease model and its isogenic control.
- Publication Part Number: 5994-3112EN
- Created: 09 Sep 2021
- 3 MB
Noninvasive and continuous monitoring of the perturbation of cellular growth following exposure to the cumulative toxicants present in water samples.
- Publication Part Number: 5994-3712EN
- Created: 07 Sep 2021
- 916 KB
xCELLigence Immunotherapy IMT Assay (anti-CD29) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3237
- Created: 14 July 2021
- 671 KB
xCELLigence Immunotherapy IMT Assay (anti-CD19) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3235
- Created: 14 July 2021
- 768 KB
xCELLigence Immunotherapy IMT Assay (anti-CD40) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3238
- Created: 14 July 2021
- 727 KB
xCELLigence Immunotherapy IMT Assay (anti-CD71) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3236
- Created: 14 July 2021
- 749 KB
必威体育登录手机A demonstration of how the Agilent xCELLigence RTCA eSight real-time imaging platform can be used to monitor induction of the unfolded protein response using a genetically encoded fluorescent sensor.
- Publication Part Number: 5994-3071EN
- Created: 16 Apr 2021
- 4 MB
必威体育登录手机A demonstration of how the Agilent xCELLigence RTCA eSight real-time imaging platform can be used to monitor phagocytosis, using a model system comprising macrophages and E.coli cells conjugated to a pH-sensitive fluorescent dye.
- Publication Part Number: 5994-3019EN
- Created: 16 Apr 2021
- 6 MB
A demonstration of how the eSight combines the strengths of real-time impedance monitoring with those of live cell imaging, to increase the information richness of your proliferation assays while simultaneously reducing the workload.
- Publication Part Number: 5994-3017EN
- Created: 17 Feb 2021
- 6 MB
To determine if the stimulation of endogenously expressed GPCRs can be monitored by the xCELLigence system, cells were stimulated with various receptor agonists, triggering either Gs-, Gi-, or Gq-mediated downstream signals.
- Publication Part Number: 5994-1940EN
- Created: 02 Feb 2021
- 3 MB
必威体育登录手机Using the Agilent xCELLigence RTCA eSight to continuously monitor CAR T cell-mediatedkilling of cancer cells over the course of multiplae days.
- Publication Part Number: 5994-1712EN
- Created: 09 Nov 2020
- 4 MB
In this application note, we used the xCELLigence RTCA CardioECR system (CardioECR system) in conjunction with hiPS-CMs for the assessment of preclinical cardiac risks.
- Publication Part Number: 5994-2076EN
- Created: 16 June 2020
- 5 MB
必威体育登录手机This application note presents a method for improving human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturation using the Agilent xCELLigence RTCA ePacer system.
- Publication Part Number: 5994-1552EN
- Created: 16 June 2020
- 5 MB